Clinical trial
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
NCT00151281 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00151281 |
|---|---|
| Title | Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma |
| Official title | Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | PEPC, Thalidomide, Rituximab |
| Enrollment | 25 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2009 |
| Completion | Apr 7, 2011 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 28, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: